Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Avandamet var større end risiciene ved behandling af patienter med type 2 diabetes mellitus.
The Committee for Medicinal Products for Human Use (CHMP) decided that Avandamet’ s benefits are greater than its risks for the treatment of type 2 diabetes mellitus patients.